Breaking News

Financial Report: Teva

May 1, 2014

Specialty revenues up 3% in the quarter

Teva
 
1Q Revenues: $5.0 billion (+2%)
 
1Q Earnings: $740 million  (+18%)
 
Comments:
Generic revenues were $2.4 billion (including API sales of $179 million), up 3% in the quarter. Specialty medicine revenues were $2.1 billion, up 3%, driven by CNS and oncology products, partially offset by lower revenues of other specialty medicines. Copaxone sales were up 1% to $1.1 billion. Azilect sales were up 23% to $114 million. Nuvigil sales were $101 million, up 22%. Provigil sales were down 13% to $21 million. Treanda sales were up 5% to $180 million. OTC revenues were $269 million, down 12%, primarily due to lower sales in Eastern Europe.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks